InfuSystem (NYSE:INFU) Downgraded by StockNews.com

StockNews.com cut shares of InfuSystem (NYSE:INFU - Free Report) from a strong-buy rating to a buy rating in a research note published on Saturday morning.

Separately, B. Riley initiated coverage on shares of InfuSystem in a research note on Thursday. They issued a buy rating and a $13.00 price objective on the stock.

InfuSystem Price Performance

NYSE INFU traded up $0.19 on Friday, reaching $6.75. The stock had a trading volume of 49,509 shares, compared to its average volume of 56,383. The stock has a market cap of $143.74 million, a P/E ratio of -675,000.00 and a beta of 1.46. InfuSystem has a 12-month low of $5.74 and a 12-month high of $10.99. The company has a current ratio of 2.07, a quick ratio of 1.64 and a debt-to-equity ratio of 0.64.

InfuSystem (NYSE:INFU - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by ($0.01). InfuSystem had a return on equity of 0.70% and a net margin of 0.28%. The business had revenue of $33.70 million for the quarter.

Hedge Funds Weigh In On InfuSystem

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers increased its holdings in shares of InfuSystem by 13.8% in the 2nd quarter. Rhumbline Advisers now owns 17,658 shares of the company's stock valued at $121,000 after purchasing an additional 2,145 shares in the last quarter. Marshall Wace LLP acquired a new position in InfuSystem during the second quarter worth about $131,000. Oppenheimer Asset Management Inc. increased its holdings in InfuSystem by 52.1% in the second quarter. Oppenheimer Asset Management Inc. now owns 26,042 shares of the company's stock valued at $178,000 after buying an additional 8,917 shares in the last quarter. Panagora Asset Management Inc. purchased a new stake in shares of InfuSystem during the 2nd quarter worth approximately $208,000. Finally, ARS Investment Partners LLC grew its holdings in shares of InfuSystem by 11.4% in the 2nd quarter. ARS Investment Partners LLC now owns 33,510 shares of the company's stock worth $229,000 after acquiring an additional 3,422 shares during the period. Institutional investors and hedge funds own 71.13% of the company's stock.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.